Market Closed -
Nyse
04:00:00 2024-05-22 pm EDT
|
5-day change
|
1st Jan Change
|
1.29
USD
|
+7.50%
|
|
+14.16%
|
-27.53%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
48.67
|
118.5
|
37.89
|
69.41
|
129.9
|
94.58
|
-
|
-
|
Enterprise Value (EV)
1 |
48.67
|
118.5
|
37.89
|
69.41
|
129.9
|
94.58
|
94.58
|
94.58
|
P/E ratio
|
-2.67
x
|
-16.5
x
|
-1.34
x
|
-4.42
x
|
19.8
x
|
10.8
x
|
2.05
x
|
1.14
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.07
x
|
7.3
x
|
0.99
x
|
1.46
x
|
1.98
x
|
1.79
x
|
0.93
x
|
0.57
x
|
EV / Revenue
|
3.07
x
|
7.3
x
|
0.99
x
|
1.46
x
|
1.98
x
|
1.79
x
|
0.93
x
|
0.57
x
|
EV / EBITDA
|
-5,348,285
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
14,838
|
32,643
|
45,557
|
50,666
|
72,952
|
73,316
|
-
|
-
|
Reference price
2 |
3.280
|
3.630
|
0.8317
|
1.370
|
1.780
|
1.290
|
1.290
|
1.290
|
Announcement Date
|
3/12/20
|
3/30/21
|
3/31/22
|
2/27/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
15.87
|
16.24
|
38.35
|
47.64
|
65.49
|
52.7
|
101.4
|
167.2
|
EBITDA
|
-9.1
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.72
|
2.71
|
-20.46
|
-13.01
|
10.46
|
8.742
|
54.79
|
105.5
|
Operating Margin
|
-67.55%
|
16.69%
|
-53.36%
|
-27.32%
|
15.97%
|
16.59%
|
54.04%
|
63.13%
|
Earnings before Tax (EBT)
1 |
-18.28
|
-6.523
|
-27.58
|
-14.4
|
8.566
|
8.752
|
54.59
|
105.1
|
Net income
1 |
-18.28
|
-6.523
|
-27.58
|
-14.93
|
8.312
|
8.89
|
54.59
|
99.89
|
Net margin
|
-115.19%
|
-40.18%
|
-71.92%
|
-31.33%
|
12.69%
|
16.87%
|
53.84%
|
59.74%
|
EPS
2 |
-1.230
|
-0.2200
|
-0.6200
|
-0.3100
|
0.0900
|
0.1200
|
0.6300
|
1.130
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/30/21
|
3/31/22
|
2/27/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
8.549
|
-
|
8.753
|
14.18
|
8.617
|
-
|
35.08
|
10.34
|
10.49
|
3.677
|
12.5
|
16.3
|
20.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.706
|
-
|
-5.524
|
-3.125
|
-2.495
|
-
|
20.42
|
-1.887
|
-5.615
|
-
|
1.734
|
4.388
|
7.476
|
Operating Margin
|
-66.74%
|
-
|
-63.11%
|
-22.03%
|
-28.95%
|
-
|
58.22%
|
-18.24%
|
-53.55%
|
-
|
13.87%
|
26.92%
|
37.01%
|
Earnings before Tax (EBT)
1 |
-6.667
|
-
|
-5.334
|
-3.567
|
-3.21
|
-
|
19.65
|
-1.719
|
-6.426
|
-
|
1.834
|
4.288
|
7.526
|
Net income
1 |
-6.667
|
-2.286
|
-5.334
|
-3.567
|
-3.74
|
-3.131
|
19.34
|
-1.852
|
-6.044
|
-
|
1.834
|
4.288
|
7.526
|
Net margin
|
-77.99%
|
-
|
-60.94%
|
-25.15%
|
-43.4%
|
-
|
55.14%
|
-17.9%
|
-57.64%
|
-
|
14.67%
|
26.31%
|
37.26%
|
EPS
2 |
-0.1400
|
-0.0500
|
-0.1100
|
-0.0700
|
-0.0700
|
-0.0500
|
0.2100
|
-0.0300
|
-0.0700
|
-0.0600
|
0.0200
|
0.0600
|
0.1000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/31/22
|
5/16/22
|
8/15/22
|
11/14/22
|
2/27/23
|
5/4/23
|
8/7/23
|
11/6/23
|
3/14/24
|
5/10/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.63
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
3.95%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/30/21
|
3/31/22
|
2/27/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
1.29
USD Average target price
12
USD Spread / Average Target +830.23% Consensus |
1st Jan change
|
Capi.
|
---|
| -27.53% | 94.58M | | +64.23% | 62.59B | | -2.31% | 41.18B | | +45.60% | 40.29B | | -8.29% | 27.9B | | +11.97% | 26.21B | | -21.16% | 19.09B | | +7.54% | 13.08B | | +25.72% | 12.26B | | +27.17% | 12.05B |
Other Biotechnology & Medical Research
|